跳至主要内容
临床试验/NCT03320369
NCT03320369已完成不适用

Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis

Children's Hospital Medical Center, Cincinnati2 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2017年9月5日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
18
试验地点
2
主要终点
Percent of Participants in Complete Histologic Remission

研究概览

简要总结

The purpose of this study is to investigate the effect of an elemental diet on adult patients with Eosinophilic Gastroenteritis

详细描述

This prospective interventional study will investigate the effect of an exclusive, six week elemental diet in adult patients with Eosinophilic Gastroenteritis

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant must be able to understand and provide informed consent
  • Males and Females ≥18 to 65 years of age;
  • Have diagnosis of EG/EGE
  • Have histologically confirmed active disease > 30 eosinophils/hpf
  • Symptomatic (have experienced symptoms within the last one months prior to enrollment).
  • Female subjects of childbearing potential must have a negative pregnancy test upon study entry
  • Female (and male) subjects with reproductive potential, must agree to use FDA approved methods of birth control for the duration of the study-specific methods may be listed, if applicable

排除标准

  • Inability or unwillingness of a participant to give written informed consent or comply with study protocol
  • Secondary causes of gastrointestinal and peripheral eosinophilia
  • Eosinophilic infiltration isolated to the esophagus.
  • Immunodeficiency states
  • Have been treated with topical swallowed steroids within the last 6 weeks or systemic steroids within the last 2 months unless repeat endoscopy is performed and shows active inflammation on these therapies in which case these medications will be allowed to be continued without dose escalation.
  • Have taken immunosuppression medication or immunomodulators within 2 months of the study unless the recent/baseline endoscopy has active histologic inflammation while on these medications. In this case, these medications will be permitted to be continued as long as the dose is not escalated during the treatment phase.
  • Have been on an elemental diet previously for six weeks with follow up endoscopy completed.
  • Have participated in any investigative drug study within 6 weeks prior to study entry.
  • Unable to complete study procedures including endoscopy.
  • Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

结局指标

主要结局

Percent of Participants in Complete Histologic Remission

时间窗: 6 weeks after treatment

Percent of patients who have achieved complete histologic remission. Complete histologic remission is defined as normalization of gastric mucosal eosinophilia (histology with less than the diagnostic threshold levels of mucosal eosinophilia (\<30 eosinophils per high power field (HPF))

次要结局

  • Percent of Participants in Partial Histologic Remission(6 weeks after treatment)
  • Mean Change From Baseline in Maximum Eosinophil Count(Baseline, 6 weeks after treatment)
  • Change From Baseline in Total Gastric Endoscopic Reference Score(Baseline, 6 weeks after treatment)
  • Change From Baseline in Symptoms of Dyspepsia (SODA)(Baseline, 6 weeks after treatment)
  • Change From Baseline in Promis Anxiety(Baseline, 6 weeks after treatment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验